Our current findings suggest that in the treatment of MASLD with metformin, miR-200a-5p may modulate the expression of AMPK/SERCA2b, thereby ameliorating lipid deposition and ER stress. Here, PRKAA2 is linked to metabolic dysfunction-associated steatotic liver disease.